Omar Benbrahim

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

Jean‐Christophe Ianotto, Aurélie Chauveau, Françoise Boyer‐Perrard et al. · Haematologica · 2017 · 66 citations · Full text

Medicine, Hematology, Oncology +17

A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy‐associated secondary immunodeficiency

Omar Benbrahim, Jean‐François Viallard, Sylvain Choquet et al. · European Journal Of Haematology · 2018 · 26 citations · Full text

Medicine, Hematology, Immunology +17

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers‐Cancès, Margaret Macro et al. · Blood · 2022 · 25 citations · Full text

Medicine, Hematology, Oncology +16

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

Mathilde Ruggiu, Florence Oberkampf, David Ghez et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2017 · 23 citations

Medicine, Hematology, Oncology +16

The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments

Omar Benbrahim, Jean‐François Viallard, Sylvain Choquet et al. · Hematology · 2018 · 23 citations · Full text

Life Sciences, Hematology, Immunology +16